A hypertensive crisis is an abrupt and severe rise in the arterial blood pressure (BP) occurring either in patients with known essential or secondary hypertension, or it may develop spontaneously. The most frequent cause for the severe and sudden increase in BP is inadequate dosing or stopping antihypertensive treatment in hypertensive patients. Severe hypertension can be defined as either a hypertensive emergency or an urgency, depending on the existence of organ damage. In hypertensive urgencies, there are no signs of acute end-organ damage, and orally administered drugs might be sufficient. In hypertensive emergencies, signs of acute end-organ damage are present, and in these cases, quickly-acting parenteral drugs must be used. The prompt recognition, assessment, and treatment of hypertensive urgencies and emergencies can decrease target organ damage and mortality. In this review, the definitions and therapeutic recommendations in a hypertensive crisis are presented in the light of the 2017 ACC/AHA Hypertension Guidelines.
INTRODUCTION
Arterial hypertension presents a very high incidence and is a frequently encountered clinical situation, affecting nearly 1 billion subjects around the world. The overall sex-and age-adjusted prevalence of hypertension (systolic/diastolic >130/80 mmHg) is 48% in males and 43% in females.
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Approximately 1-2% of subjects with chronic hypertension present acute elevations of blood pressure (BP) that require urgent therapeutic measures, while more than half of subjects presenting in the emergency department with hypertensive crisis have not been compliant to their blood pressure-lowering medication within the preceding days or weeks.
DEFINITIONS
A hypertensive crisis is an abrupt increase in the systolic BP (SBP) over 180 mmHg and/or elevation of diastolic BP (DBP) over 120 mmHg. Based on the existence of acute end-organ damage, a hypertensive crisis can be defined as a hypertensive emergency or urgency. 1, 3 A hypertensive emergency is a critical rise in BP (of more than 180/120 mmHg) with associated newly developed, progressive or deteriorating target organ injury. Instances of target organ injury comprise hypertensive encephalopathy, intracerebral hemorrhage, acute ischemic stroke, acute myocardial infraction, acute left ventricular failure with pulmonary edema, unstable angina, dissecting aortic aneurysm, acute renal failure, and eclampsia. 1, 4 In 2017, Guiga et al. published data on mortality rates in a 670-patient cohort presenting with hypertensive emergencies, and the one-year associated mortality rate was over 79%, while the median survival period was 10.4 months in subjects in which the emergency was untreated.
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Subjects with chronic hypertension are regularly able to tolerate significantly higher BP levels than those with previously normal BP values. A review article focusing on the epidemiology, causes, pathophysiology, and prognosis of hypertensive crises, published in 2017 by Ipek et al., re- vealed that in the evolution and prognosis of hypertensive emergencies, the rate of BP rise seems to be more important than the actual BP level. 6 In hypertensive emergencies, fast reduction of BP is recommended (not necessarily to normal values) in order to avoid and limit additional target organ injury. In adults with a hypertensive emergency, hospital admission and close supervision in an intensive cardiac care facility is recommended, to continuously monitor arterial pressure levels, to assess and treat target organ injury, as well as to administer intravenous antihypertensive
medication. Both current European Society of Hypertension (ESH) and European Society of Cardiology (ESC), as well as American College of Cardiology (ACC) and American Heart
Association (AHA) guidelines discourage the use of oral antihypertensive treatment for hypertensive emergencies.
1,3
Hypertensive urgencies are defined as severe BP elevation in chronic hypertensive patients with no acute target organ injury or dysfunction. In the majority of cases, these patients are non-adherent to the prescribed antihypertensive regimen and do not present with clinical or laboratory signs of acute target organ injury. In hypertensive urgencies, BP levels are frequently lowered in the emergency department, with the use of oral medication, and patients do not require hospital admission, but are, however, followed-up in outpatient settings. The physical examination includes assessment of pulses in all limbs, auscultation of the lungs (rales suggestive for pulmonary edema), the heart (murmurs, gallop rhythm), and the renal arteries (bruits), as well as a neurologic and ocular (fundoscopic) check-up.
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Laboratory exams (full blood count, creatinine, urea, electrolytes, urine analysis), ECG, chest X-ray, echocardiography, CT (chest/head), MRI should be performed.
Based on the physical examination, laboratory examinations, and imaging, the clinician is able to distinguish between a hypertensive emergency and urgency, and to formulate a patient management plan for further diagnostic testing and therapeutic measures. 
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A Cochrane systematic review on therapeutic measures applied in hypertensive emergencies, which studied 15 randomized controlled trials and 869 subjects treated with seven drug classes, did not find sufficient data for defining which antihypertensive medication is the most efficient in treating hypertensive emergencies and decreasing mortality. 25 Randomized clinical trials are needed to investigate mortality and outcomes in patients with hypertensive emergencies treated with different antihypertensive drugs, and rate and grade BP lowering in a hypertensive emergency.
According to actual guidelines (ESH/ESC and ACC/AHA),
in hypertensive emergencies, continuous intravenous ad-ministration of short-acting antihypertensive therapies is recommended. 1, 23 Choosing an antihypertensive class should be grounded on its pharmacological characteristics, the degree and advancement of target organ damage, the required rate of BP reduction, and comorbidities. 27 The dosage of these agents must be titrable for a controllable antihypertensive effect and for the prevention of further target organ damage, because an excessive and rapid lowering of BP values may cause coronary, cerebral, or renal ischemia.
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INTRAVENOUS ANTIHYPERTENSIVE MEDICATION IN HYPERTENSIVE EMERGENCIES
CALCIUM CHANNEL BLOCKERS -DIHYDROPYRIDINES
Nicardipine is a second-generation short-acting dihydropyridine-type calcium-channel blocker. The onset of action of intravenously administered nicardipine is from 5 to 15 minutes, the duration of action is 4 to 6 hours. dose in an acute ischemic stroke and a hemorrhagic stroke subject, respectively. They concluded that nicardipine as an intravenous medication is effective and safe in these situations.
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The recommended initial infusion rate of nicardipine is 5 mg/h, which may be increased every 5 minutes by 2.5 mg/h, up to a maximum of 15 mg/h until the chosen BP reduction is attained. There is no required dose modification in case of elderly patients, and there is no dependence on the patient's weight. Nicardipine is contraindicated in advanced aortic stenosis.
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Clevidipine is a third-generation dihydropyridine calcium-channel blocker with ultrashort action, with a highly selective arteriolar vasodilator effect. 33, 34 This effect is due to a selective inhibition of the influx of calcium through the L-type channel, producing vasodilatation of the small arteries and reduction of peripheral vascular resistance, thus reducing the afterload without affecting cardiac filling pressures or reflex tachycardia. Nitroglycerin is a powerful venous vasodilator that only acts on the arterial vascular tonus at increased doses and lowers BP by decreasing venous return (preload) and cardiac output. 8 The initial recommended dose is 5 mcg/min, which can be increased in increments of 5 mcg/min every 3-5 min to a maximum of 20 mcg/min. Tolerance to the hemodynamic effects of nitroglycerin may limit its clinical usefulness. 21 In the ECLIPSE trial, clevidipine was more effective compared with nitroglycerine (p = 0.0006) in sustaining BP in the target range. There was no difference between the nitroglycerin group and the clevidipine-and nitroprusside-treated patients regarding the rate of myocardial infarction, stroke, or renal failure.
35
Headache is the most common adverse effect of nitroglycerin treatment, and another potential side effect is low blood pressure with reflex tachycardia, which can be aggravated by volume depletion typically used in hypertensive emergencies. 38 Another undesirable effect of nitroglycerin is compromised cerebral and renal perfusion, therefore, its use is recommended only in subjects presenting an acute coronary syndrome or acute pulmonary edema and is contraindicated in patients with volume depletion.
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DIRECT VASODILATORS
Hydralazine inhibits calcium release from the sarcoplasmic reticulum in arteriolar smooth muscle fibers, thus leading to peripheral vasodilation, which in turn decreases cardiac afterload and improves left ventricular function in subjects with heart failure. 39 However, hydralazine is not regularly used as a first-line therapy in the treatment of hypertensive emergencies as it presents prolonged and unpredictable blood pressure-lowering properties. The results showed that the esmolol group presented significantly lower rates of myocardial ischemic events and less episodes of hypotension or bradycardia compared to controls. 29 Contraindications for the use of esmolol comprise subjects under concomitant beta-blocker therapy, low heart rate, acute or decompensated heart failure.
Continuous heart rate monitoring is recommended for patients receiving esmolol in order to promptly recognize severe bradycardia and notice heart failure symptoms, as they may worsen. 1 The metabolism of esmolol is not dependent on kidney or liver function, and it is considered "an ideal ß-adrenergic antagonist" in critically ill subjects due to its pharmacokinetic properties.
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Labetalol, a non-selective alpha-and beta-adrenergic receptor blocker, presents vasodilator properties in the pe- This dose can be repeated every 4-6 hours. Labetalol is contraindicated in bronchial asthma and chronic obstructive pulmonary disease. Due to its negative inotrope and chronotropic effects, it should not be given in subjects with heart failure and with second-or third-degree atrioventricular block or bradycardia. 1, 28 Phentolamine is a competitive α-adrenergic receptor antagonist with greater affinity for the α1-than α2-receptor subtype, producing a significant reduction in systemic vascular resistance and an increase in cardiac output, myocardial oxygen demand, and heart rate. Adverse effects include reflex tachycardia and fluid retention, and it is contraindicated in myocardial ischemia.
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DOPAMINE 1-RECEPTOR SELECTIVE AGONIST
Fenoldopam is an agonist for D1-like dopamine receptors, with moderate affinity to α2-adrenergic receptors. As a D1-dopamine receptor agonist is a rapid-acting vasodilator, it leads to a decreased peripheral vascular resistance and increased blood flow to the kidneys, while also having minimal diuretic (natriuretic) effects. 40 This favorable effect on renal perfusion was confirmed by a meta-analysis by Gillies et al., on 6 randomized controlled trials, which found that patients who had received fenoldopam treatment in the perioperative period, presented a significantly lower rate of acute kidney injury following a major surgical intervention. 40 Fenoldopam is contraindicated in subjects at high risk of conditions with increased intraocular (glaucoma) or intracranial pressure and those with sulfite allergy. 1 Adverse effects are hypotension and severe headache.
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ACE INHIBITORS
Enalaprilat is an angiotensin-converting enzyme (ACE)
inhibitor with vasodilator properties due to the decreased production of angiotensin II and increased levels of bradykinin. In patients with hypertension, the administration of enalaprilat produces the reduction of total peripheral resistance with slight influence on the heart rate or cardiac output. 41 In a retrospective cohort study by Avaz et al., the administration of bolus intravenous enalaprilat was evaluated when administered to hypertensive patients with acute heart failure, resulting in a substantial reduction in systolic BP. The treatment was well tolerated, with limited hypotension and no adverse effect on kidney function. 41 The recommended dose of enalaprilat is 1.25 mg administered over a 5-minute period. The results were the first to prove that clevidipine is a safe alternative for kidney failure patients with severely increased blood pressure, and continuous prolonged intra-venous infusion of clevidipine allowed a successful switch to oral antihypertensive treatment.
As we presented above, fenoldopam lowers the peripheral vascular resistance and concomitantly stimulates renal perfusion in subjects with non-impaired kidney function, as well as in those with chronic renal insufficiency.
Data from experimental acute kidney injury models advocate that it also has anti-inflammatory properties, independent of its vasodilator actions.
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ECLAMPSIA OR PREECLAMPSIA
The target systolic blood pressure in eclamptic or preeclamptic women is below 140 mmHg within the first hour. 49 Hydralazine, labetalol, and nicardipine are the 
PERIOPERATIVE HYPERTENSION
Perioperative hypertension is defined as a BP of 160/90 mmHg or higher or an SBP elevation of at least 20% of the preoperative value, that persists for longer than 15 minutes.
Intraoperative hypertension is most frequently encountered during anesthesia induction and airway manipulation. 50 Intravenous administration of clevidipine, esmolol, nicardipine, or nitroglycerin are the elective therapeutic management option for this hypertensive emergency. In subjects with spontaneous intracerebral hemorrhage presenting within the first 6 hours from onset, with a systolic BP ranging from 150 to 220 mmHg, immediate lowering of systolic BP below 140 mmHg can be potentially harmful. [54] [55] [56] The safety and feasibility of intensive BP lowering in patients with acute hemorrhagic stroke was investigated concern. The results of this study revealed that intensive BP treatment was not related to impaired perihematomal cerebral blood flow compared to the SOC group. 57 This finding further supports the safety of early BP lowering in acute intracerebral bleeding. However, it also indicates that excessive BP treatment has no effect on diminishing the perihematomal edema.
ACUTE ISCHEMIC STROKE
For acute ischemic stroke, the ideal therapeutic agents are labetalol and nicardipine. In the CATIS trial, which included 4,071 hypertensive patients with non-thrombolysed ischemic stroke within 48 hours of onset, subjects were randomly assigned to either receive antihypertensive treatment (to achieve a BP of under 140/90 mmHg within 7 days) or to discontinue all antihypertensive medications (control) during hospitalization. The conclusion of this trial was that in subjects with acute ischemic stroke, the administration of BP-lowering medications, compared with the absence of hypertensive drugs, did not reduce the risk of death and major disability at 14 days or at hospital discharge.
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TREATMENT OF HYPERTENSIVE URGENCIES
Hypertensive urgencies represent the severe elevation of BP (>180/120 mmHg) but without signs of acute target organ damage. In these individuals, BP should be lowered progressively, over a period of 24 to 48 hours, and for orally administered antihypertensive drugs, a close follow-up in outpatient settings is strongly recommended.
BP lowering should be gradual, as there is no confirmed benefit from a rapid decrease in BP in patients without any symptoms of acute target organ damage. Also, a rapid fall in BP could produce important organ damage. 
CONCLUSIONS
Patients presenting in the emergency department with severely increased arterial pressure require careful examination for signs and symptoms of target organ damage.
A proper initial assessment in needed in order to further direct patient management, for identification and treatment of possible life threatening complications such as aortic dissection, acute coronary syndromes, acute heart failure or cerebrovascular events. The prompt recognition, assessment and treatment of hypertensive urgencies and emergencies can decrease organ damage and mortality.
